Independent Research
ARWR Analysis
5 pieces of research on Arrowhead Pharmaceuticals, Inc.. We find the signal management buried in the earnings call.
5signal analyses
0news briefs
latest: Oct 16, 2026
Signal Analysis (3)
Analysis
Arrowhead Insiders Sold at $87; UBS Now Targets $109
Arrowhead Pharmaceuticals' interim Alzheimer's data showed 73% mean CSF tau reduction at Day 105, prompting UBS to raise its price target to $109 on October 15.…
Read analysis →Analysis
Arrowhead's 750-Patient Heart Data: A $12B Test
Arrowhead Pharmaceuticals carries a $12 billion market cap sustained entirely by episodic milestone payments from GSK, Takeda, Amgen, and Sarepta, with no appro…
Read analysis →Analysis
Arrowhead Directors Sell $1.19M Ahead of Key Heart Data
Two Arrowhead Pharmaceuticals directors sold a combined $1.19 million in shares on August 18, days before a 750-patient cardiovascular dataset is due at a late-…
Read analysis →